Pfizer vaccine, high protection even after 6 months from the shield injection. A new updated analysis “shows what the vaccine” from Pfizer and BioNTech “has 91.3% efficacy against Covid 19, measured from 7 days to 6 months after the second dose“This was communicated by the two companies, reporting the results of the analysis conducted on the 46,307 participants in the study (more than 12 thousand received the vaccine at least 6 months ago).
The examination of 927 confirmed symptomatic cases of Covid confirms “the high efficacy and the absence of serious safety problems up to six months after the second dose in the updated analysis of the historical study on the vaccine”. Vaccine which was found to be “100% effective in the prevention of severe diseases as defined by the US Centers for Disease Control and Prevention and 95.3% effective in the prevention of severe Covid as defined by the US FDA”.
“These data – commented Pfizer’s president and CEO, Albert Bourla – confirm the favorable efficacy and safety profile of our vaccine and allow us to submit a Biologics License Application to the United States FDA”, which is the application for approval. of an organic product. “The high vaccine efficacy observed up to six months after a second dose and against the variant prevalent in South Africa provides further confidence in the overall efficacy of our vaccine.”
“This is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a long-term follow-up,” added Ugur Sahin, CEO and co-founder of BioNTech. “These data also provide the first clinical results that a vaccine can effectively protect against variants currently in circulation, a crucial factor in achieving herd immunity and ending this pandemic for the global population.”
The reference is to the data observed in South Africa, where variant B.1.351 is prevalent and 800 study participants were enrolled: 9 cases of Covid observed, all in the placebo group, indicating a vaccine efficacy of 100%. In an exploratory analysis, the 9 strains were sequenced and 6 were confirmed to be variant. These data support previous results from immunogenicity studies showing that the mRna vaccine induced a “robust neutralizing antibody response” to the South African variant and, “although inferior to the ‘wild-type’ strain, does not appear to affect the observed high efficacy. against this variant “.
Pfizer / BioNtech’s anti-Covid vaccine was in fact “100% effective in preventing Covid-19 cases in South Africa, where the Sars-CoV-2 variant” B.1.351 “is prevalent, explained the two companies, reporting an updated analysis of 927 confirmed symptomatic cases of Covid observed in their pivotal phase 3 study through March 13, 2021.
“Vaccine safety is now evaluated in more than 44,000 participants aged 16 and older, with over 12,000 vaccinated participants having a follow-up of at least six months after the second dose.” The companies plan to “soon share these findings with regulatory agencies around the world,” reads the note released by the companies.
Export vaccines, Pfizer: “EU rules create uncertainty”
The new rules imposed by the EU on the export of vaccines hinder the production of immunizers. This is what Danny Hendrikse, vice president of Pfizer complains, according to which the need for approval by Brussels before the export of any supply of vaccines or components necessary for their production has caused the US pharmaceutical giant “a significant burden. administrative and some uncertainty “.
“Ultimately, we would like our colleagues to focus on the production and distribution of vaccines,” Hendrikse said, according to the Times and other British newspapers. The process of acquiring all the raw materials necessary for the production of vaccines, explained the vice president of Pfizer, is “particularly complex”, because “the components come not only from Europe, but from all over the world”. To make a dose, Hendrikse explained, it takes 280 components from 86 suppliers in 19 countries.
The words of Pfizer’s vice president, which through the plant in Belgium supplies over 70 countries, including the United Kingdom, are particularly emphasized by the British press, in the light of the dispute between London and Brussels over the control of exports of vaccines and components. The EU has threatened to block exports of vaccines to Britain if AstraZeneca does not increase supplies to the continent.